PGI13 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
Abstract
Authors
C. Fioratti M.L. Rachid R. Baida T. Decimoni M.J. Brunelli